Home › US companies › Repligen

Repligen

RGEN · Nasdaq · Biological Products, (No Diagnostic Substances)
Insider buys (12 months)
0
Insider sales (12 months)
$15.3M
8-K reports (12 months)
11
Tracked investors holding
1

At a glance

Repligen reported 2025 revenue of $738.3M, up 16.4% from $634.4M in 2024. Over 4 years since 2021 ($670.5M), that is growth of about 2.4% a year. Operating margin was 7.5%, down from 24.9% in 2021. Revenue peaked in 2022 at $801.5M. The company posted a loss in 2024.

In the last 12 months 5 insiders reported 0 open-market purchases and 13 sales ($15.3M). 10 of the sales were made under pre-arranged 10b5-1 plans. The largest was a sale of $3.9M by Director Anthony Hunt on Nov 13, 2025.

Repligen filed 11 current reports (Form 8-K) in the last 12 months, most often for results of operations (5), officer or director change (2), unregistered equity sale (1) and acquisition or disposal completed (1). The latest officer or director change was reported on Sep 15, 2026. It reported a material agreement or a completed acquisition or disposal 2 times.

1 of the 20 investors tracked here held Repligen at the last quarter end, worth $11K combined. It is the largest weight for Duquesne Family Office (0.2% of its portfolio). New this quarter: Duquesne Family Office.

Annual results

2021
Revenue $670.5M
Op. $167.2M
2022
Revenue $801.5M
Op. $224.7M
2023
Revenue $632.4M
Op. $47.7M
2024
Revenue $634.4M
Op. -$35.1M
2025
Revenue $738.3M
Op. $55.2M
RevenueOperating income (or net income)SEC XBRL annual filings, fiscal years mapped to calendar years
Year20212022202320242025
Net income$128.3M$186M$35.6M-$25.5M$48.9M
Diluted EPS$2.24$3.24$0.63$-0.46$0.86

Fiscal year ends Dec 31 · incorporated in DE

Tracked investors holding (13F)

Duquesne Family OfficeNew$11K · 0.2%

Weight is the share of each investor's portfolio, as of the quarter end.

Current reports (8-K, last 12 months)

Insider open-market trades (last 12 months)

Source: SEC EDGAR. How figures are combined